Using 4-drug combination therapy adds up for man with PAH: Case
A 68-year-old man with severe PAH and multiple coexisting conditions experienced marked improvement after receiving combination therapy.| Pulmonary Hypertension News
A 68-year-old man with severe PAH and multiple coexisting conditions experienced marked improvement after receiving combination therapy.| Pulmonary Hypertension News
Three months of CS1 therapy boosted quality of life, while symptoms tied to heart failure and clinical worsening and mortality risk declined.| Pulmonary Hypertension News
The investigational therapy CS1 led to beneficial changes in for people with pulmonary arterial hypertension in a Phase 2a clinical trial.| Pulmonary Hypertension News
Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy candidate CS1.| Pulmonary Hypertension News
